| Previous Close | 0.0003 |
| Open | 0.0003 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0003 - 0.0003 |
| 52 Week Range | 0.0001 - 0.0023 |
| Volume | 1,486,758 |
| Avg. Volume | 6,407,921 |
| Market Cap | 1.23M |
| Beta (3Y Monthly) | 11.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.53 |
CORAL SPRINGS, Fla., April 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharma Corporation (NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company has responded to an FDA warning letter that was issued on March 11th regarding the company’s website and social media sites for the sales and marketing of their Nyloxin® products.
The Food and Drug Administration said on Tuesday it had posted a warning letter to Nutra Pharma Corp. for illegally marketing unapproved products for treating pain and addiction. "Health fraud scams like these are inexcusable," said FDA Commissioner Scott Gottlieb. Nutra Pharma makes a line of products that supposedly contain cobra venom, something the company says can be used to treat chronic pain, cancer, arthritis and heroin addiction. "These products have not been demonstrated to be safe or effective and may keep some patients from seeking appropriate, FDA-approved therapies," the FDA said in a statement. The regulatory agency is seeking a response from Nutra Pharma within 15 working days. Nutra Pharma trades over the counter.